Search research articles
Contact Us
Filters
Showing results (1-10 of 29) with videos related to
Page
of 3
Sort By:
The British Journal of Dermatology
|
August 25, 2018
Towards a better understanding of outcome measurement instruments for atopic eczema
J R Chalmers, S Danby
The British Journal of Dermatology
|
September 26, 2015
How to teleconference effectively
H C Williams, J R Chalmers
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|
April 5, 2001
Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs
J R Chalmers, M B Bobek, M A Militello
Clinical and Experimental Dermatology
|
November 12, 2020
Scoping the international impact from four independent national dermatology trials
H C Williams, N K Rogers, J R Chalmers, et al.
The British Journal of Dermatology
|
January 23, 2018
How should minimally important change scores for the Patient-Oriented Eczema Measure be interpreted? A validation using varied methods
L Howells, S Ratib, J R Chalmers, et al.
The British Journal of Dermatology
|
March 26, 2016
Reporting of symptoms in randomized controlled trials of atopic eczema treatments: a systematic review
L A A Gerbens, J R Chalmers, N K Rogers, et al.
The British Journal of Dermatology
|
March 31, 2015
Clearing up misunderstandings around core outcomes for atopic dermatitis
H C Williams, C Apfelbacher, J R Chalmers, et al.
The British Journal of Dermatology
|
March 14, 2020
Assessing uptake of the Harmonising Outcome Measures for Eczema (HOME) Core Outcome Set and recommended instruments
R Vincent, J R Chalmers, C McWilliams, et al.
The British Journal of Dermatology
|
February 17, 2015
A randomized controlled trial to compare the safety and effectiveness of doxycycline (200 mg daily) with oral prednisolone (0.5 mg kg(-1) daily) for initial treatment of bullous pemphigoid: a protocol for the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) Trial
J R Chalmers, F Wojnarowska, G Kirtschig, et al.
BMC Medical Research Methodology
|
February 5, 2021
Using electronic health records to inform trial feasibility in a rare autoimmune blistering skin disease in England
M S M Persson, K E Harman, K S Thomas, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 29) with videos related to
Sort By:
Page
of 3
The British Journal of Dermatology
|
August 25, 2018
Towards a better understanding of outcome measurement instruments for atopic eczema
J R Chalmers, S Danby
The British Journal of Dermatology
|
September 26, 2015
How to teleconference effectively
H C Williams, J R Chalmers
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|
April 5, 2001
Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs
J R Chalmers, M B Bobek, M A Militello
Clinical and Experimental Dermatology
|
November 12, 2020
Scoping the international impact from four independent national dermatology trials
H C Williams, N K Rogers, J R Chalmers, et al.
The British Journal of Dermatology
|
January 23, 2018
How should minimally important change scores for the Patient-Oriented Eczema Measure be interpreted? A validation using varied methods
L Howells, S Ratib, J R Chalmers, et al.
The British Journal of Dermatology
|
March 26, 2016
Reporting of symptoms in randomized controlled trials of atopic eczema treatments: a systematic review
L A A Gerbens, J R Chalmers, N K Rogers, et al.
The British Journal of Dermatology
|
March 31, 2015
Clearing up misunderstandings around core outcomes for atopic dermatitis
H C Williams, C Apfelbacher, J R Chalmers, et al.
The British Journal of Dermatology
|
March 14, 2020
Assessing uptake of the Harmonising Outcome Measures for Eczema (HOME) Core Outcome Set and recommended instruments
R Vincent, J R Chalmers, C McWilliams, et al.
The British Journal of Dermatology
|
February 17, 2015
A randomized controlled trial to compare the safety and effectiveness of doxycycline (200 mg daily) with oral prednisolone (0.5 mg kg(-1) daily) for initial treatment of bullous pemphigoid: a protocol for the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) Trial
J R Chalmers, F Wojnarowska, G Kirtschig, et al.
BMC Medical Research Methodology
|
February 5, 2021
Using electronic health records to inform trial feasibility in a rare autoimmune blistering skin disease in England
M S M Persson, K E Harman, K S Thomas, et al.
Page
of 3